Of note, another study recently reported an anti-tumoral effect of the IL-33/ST2 pathway on the development of sporadic CRC, with an increased frequency of tumor-infiltrating FOXP3+ Tregs in BM chimeric mice lacking ST2 expression on both the hematopoietic and the radio-resistant compartments.34 These differences with our investigation may rely on the type of CRC model applied—AOM only versus AOM and DSS treatment—or the genetic background of the St2−/− mice used—BALB/c versus C57BL/6J. The gene discussed is IL33; the disease is colorectal carcinoma.